ViroXis Corporation, Inc.
acquired by TFSSan Antonio, US · 1 known investors
Mid-stage drug developer of botanical anti-viral topical prescription candidates for skin diseases; acquired by TFS Corporation in 2017.
Founders & leadership
Board
AD
Alan DeanBoard director
IW
Ian William David ClementsBoard director
PC
Paul CastellaBoard director
GF
Gary FrashierBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$1M disclosed across 1 round · 2012
▶$1MraisedMar 2012 · 6 investors · PharmaceuticalsRule 506(b)
▶$1MraisedMar 2012 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Alan DeanDirector
- Ian William David ClementsExecutive Officer, Director
- Gary FrashierDirector
- Paul CastellaDirector
- Offering amount
- $10M
- Amount sold
- $1M
- First sale
- Feb 2012
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does ViroXis Corporation, Inc. do?
- Mid-stage drug developer of botanical anti-viral topical prescription candidates for skin diseases; acquired by TFS Corporation in 2017.
- Who are ViroXis Corporation, Inc.'s investors?
- ViroXis Corporation, Inc.'s investors include Targeted Technology Funds.
- How much funding has ViroXis Corporation, Inc. raised?
- ViroXis Corporation, Inc. has disclosed $1M raised across 1 round.
- Who acquired ViroXis Corporation, Inc.?
- ViroXis Corporation, Inc. was acquired by TFS.
- Where is ViroXis Corporation, Inc. headquartered?
- ViroXis Corporation, Inc. is headquartered in San Antonio, US.